We canât show the full text here under this license. Use the link below to read it at the source.
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes
Worsening Blood Sugar Control in Type 2 Diabetes Linked to Shortage of a Key Glucose-Regulating Hormone Treatment
AI simplified
Abstract
The average hemoglobin A1c level increased from 7.0%±0.9% to 8.1%±1.4% within 3 months after discontinuing dulaglutide in individuals with type 2 diabetes.
- Discontinuation of dulaglutide is associated with significant deterioration in glycemic control.
- Fasting glucose levels rose from 129±31 to 156±50 mg/dL following the cessation of the medication.
- Alternative treatments, such as dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporter-2 inhibitors, did not sufficiently compensate for the loss of GLP-1 receptor agonist therapy.
- The findings underscore the critical role of continuous GLP-1 receptor agonist therapy in managing metabolic health.
AI simplified
Key numbers
8.1%±1.4%
Increase in Hemoglobin A1c
HbA1c levels rose from 7.0%±0.9% to 8.1%±1.4% within 3 months.
156±50 mg/dL
Increase in Fasting Glucose
Fasting glucose levels increased from 129±31 to 156±50 mg/dL.